CN114375293A - 异喹啉类化合物及其制备方法和应用 - Google Patents

异喹啉类化合物及其制备方法和应用 Download PDF

Info

Publication number
CN114375293A
CN114375293A CN202180004765.0A CN202180004765A CN114375293A CN 114375293 A CN114375293 A CN 114375293A CN 202180004765 A CN202180004765 A CN 202180004765A CN 114375293 A CN114375293 A CN 114375293A
Authority
CN
China
Prior art keywords
compound
alkyl
substituted
group
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180004765.0A
Other languages
English (en)
Other versions
CN114375293B (zh
Inventor
沈敬山
高召兵
肖庚富
李佳
杨飞瀑
张磊砢
夏冰清
蒋翔锐
何洋
蒋华良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Wuhan Institute of Virology of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Wuhan Institute of Virology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Wuhan Institute of Virology of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN114375293A publication Critical patent/CN114375293A/zh
Application granted granted Critical
Publication of CN114375293B publication Critical patent/CN114375293B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明提供了一种式(I)表示的异喹啉类化合物、其药学上可接受的盐、其对映异构体、非对映异构体、外消旋体，结晶水合物及溶剂合物及其组合物在抗病毒中的应用。其中，R1、R2、R3和R4如说明书中所定义。本发明还提供了所述化合物的制备方法以及其用于制备抑制病毒的抑制剂和/或预防和/或治疗病毒引起的呼吸道感染、肺炎等相关疾病的药物的用途。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180004765.0A 2020-06-12 2021-01-11 异喹啉类化合物及其制备方法和应用 Active CN114375293B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202010534755 2020-06-12
CN2020105347555 2020-06-12
CN202010754738 2020-06-28
CN2020107547382 2020-06-28
CN202011197404 2020-10-30
CN2020111974046 2020-10-30
PCT/CN2021/071113 WO2021248909A1 (zh) 2020-06-12 2021-01-11 异喹啉类化合物及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN114375293A true CN114375293A (zh) 2022-04-19
CN114375293B CN114375293B (zh) 2024-08-06

Family

ID=78845133

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180004765.0A Active CN114375293B (zh) 2020-06-12 2021-01-11 异喹啉类化合物及其制备方法和应用

Country Status (3)

Country Link
US (1) US20240309012A1 (zh)
CN (1) CN114375293B (zh)
WO (1) WO2021248909A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516143A (zh) * 2020-11-30 2021-03-19 重庆医科大学 双苄四氢异喹啉衍生物在制备抗冠状病毒药物中的应用
CN115197231A (zh) * 2022-08-15 2022-10-18 北京中医药大学 广谱抗病毒中药单体小檗胺及其应用
WO2023104213A1 (zh) * 2021-12-10 2023-06-15 中国科学院上海药物研究所 环状双苄基四氢异喹啉类化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02111777A (ja) * 1988-10-20 1990-04-24 Kaken Shiyouyaku Kk ビスベンジルイソキノリン誘導体
CN103181896A (zh) * 2011-12-30 2013-07-03 沈阳药科大学 一种含有小檗胺类药物的脂质体制剂及其制备方法
WO2020116606A1 (ja) * 2018-12-06 2020-06-11 キリンホールディングス株式会社 Ｔ細胞又はｎｋ細胞の製造方法、ｔ細胞又はｎｋ細胞の培養用培地、ｔ細胞又はｎｋ細胞の培養方法、未分化ｔ細胞の未分化状態を維持する方法及びｔ細胞又はｎｋ細胞の増殖促進剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02111777A (ja) * 1988-10-20 1990-04-24 Kaken Shiyouyaku Kk ビスベンジルイソキノリン誘導体
CN103181896A (zh) * 2011-12-30 2013-07-03 沈阳药科大学 一种含有小檗胺类药物的脂质体制剂及其制备方法
WO2020116606A1 (ja) * 2018-12-06 2020-06-11 キリンホールディングス株式会社 Ｔ細胞又はｎｋ細胞の製造方法、ｔ細胞又はｎｋ細胞の培養用培地、ｔ細胞又はｎｋ細胞の培養方法、未分化ｔ細胞の未分化状態を維持する方法及びｔ細胞又はｎｋ細胞の増殖促進剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DONG EON KIM等: "Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, Fangchinoline, and Cepharanthine, Inhibit Human Coronavirus OC43 Infetion of MRC-5 Human Lung Cells", 《BIOMOLECULES》 *
KO MEEHYUN等: "Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells：Nafamostat is the most potent antiviral drug candidate", 《JOURNAL OF MEDICAL VIROLOGY》 *
XIUYUAN OU等: "Characterization of spike glycoprotein of 2019-nCoV on virus entry and its immune cross-reactivity with spike glycoprotein of SARS-CoV", 《NATURE COMMUNICATIONS》 *
陈庆华等: "小檗胺酚羟基的烷基化", 《化学学报》 *
黄文龙等: "钙拮抗剂的研究：蝙蝠葛碱和小孽胺衍生物的合成", 《医药工业》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516143A (zh) * 2020-11-30 2021-03-19 重庆医科大学 双苄四氢异喹啉衍生物在制备抗冠状病毒药物中的应用
WO2023104213A1 (zh) * 2021-12-10 2023-06-15 中国科学院上海药物研究所 环状双苄基四氢异喹啉类化合物及其制备方法和应用
CN115197231A (zh) * 2022-08-15 2022-10-18 北京中医药大学 广谱抗病毒中药单体小檗胺及其应用
CN115197231B (zh) * 2022-08-15 2023-01-17 北京中医药大学 广谱抗病毒中药单体小檗胺及其应用

Also Published As

Publication number Publication date
US20240309012A1 (en) 2024-09-19
WO2021248909A1 (zh) 2021-12-16
CN114375293B (zh) 2024-08-06

Similar Documents

Publication Publication Date Title
CN110016025B (zh) 一种免疫调节剂
CN114375293A (zh) 异喹啉类化合物及其制备方法和应用
US10851115B2 (en) Heterocyclic compounds as RSV inhibitors
CN104031104B (zh) 新的核苷氨基磷酸酯化合物及其应用
KR20220101083A (ko) 항바이러스 헤테로사이클릭 화합물
KR101551238B1 (ko) 신규한 ｈｉｖ 역전사효소 억제제
WO2015124063A1 (zh) 丙肝病毒抑制剂及其制药用途
KR20210024574A (ko) 세포 괴사 억제제 및 이의 제조 방법과 용도
WO2020011246A1 (zh) 含苯环的化合物、其制备方法及应用
TW201138786A (en) Therapeutic compounds
WO2019223732A1 (zh) 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
CN110461836B (zh) 一种选择性抑制激酶化合物及其用途
CN112574269A (zh) 嘌呤核苷类化合物及其用途
CN109134481B (zh) 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
WO2023195529A1 (ja) ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
TW202300144A (zh) 抗病毒雜環化合物
WO2017173960A1 (zh) 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
CN115698011A (zh) Pb2抑制剂及其制备方法和用途
JP4038245B2 (ja) 新規なフェナンスリジニウム誘導体
CN107074876B (zh) 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
JP2023505213A (ja) 嚢胞性線維症の治療のための化合物および方法
WO2023104213A1 (zh) 环状双苄基四氢异喹啉类化合物及其制备方法和应用
WO2020210246A1 (en) Heterocyclic compounds as rsv inhibitors
WO2023200441A1 (en) Antiviral heterocyclic compounds
WO2022211812A1 (en) Antiviral heterocyclic compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant